<DOC>
	<DOCNO>NCT00832221</DOCNO>
	<brief_summary>The aim study relate pharmacokinetics two different formulation quetiapine PET measure receptor occupancy brain healthy subject .</brief_summary>
	<brief_title>Positron Emission Tomography ( PET ) Study With 11CRaclopride Determine Central D2 Dopamine Occupancy SEROQUEL</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Raclopride</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>Normal MRI scan Body mass index 1930 kg/m2 weight 50100 kg Clinically normal physical finding , medical history laboratory value Trauma sickness last 2 week first PET examination . A history presence neurological , haematological , psychiatric , gastrointestinal , hepatic , pulmonary , renal disease condition judge Investigator Any previous participation PET study Subjects suffer claustrophobia</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>PET</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Depression</keyword>
	<keyword>SEROQUEL</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>Drug profile comparison</keyword>
</DOC>